ABBV has pulled back 3.2% this week to $250.94 — its first meaningful retreat since the mid-June trough — arriving just days after Q2 results that the analyst community greeted with fresh target raises but the market answered with selling.
The most telling story this week is the gap between what analysts say and what the price is doing. Barclays lifted its target to $300 from $275 just two days after the Q2 print, maintaining Overweight. That follows a wave of July upgrades — JP Morgan at $280, Wells Fargo at $295, BMO also at $300 — that pushed the consensus mean to $269.50, now implying roughly 7% upside from current levels. That gap has widened since last week when the stock traded near $259 and consensus implied just 3%. The Street is broadly bullish. The caution comes from Citigroup and UBS, both holding Neutral with targets at $260 — a level the stock has now slipped back below. On valuation, the PE runs at 16.7x and EV/EBITDA at 14.7x, with EV/EBITDA compressing about 0.44x over the past month. The forward EPS growth factor scores in the 99th percentile, while the EPS surprise factor ranks in just the 9th — a divergence worth noting.
Positioning tells a quiet story. Short interest has ticked up 12.5% on the week to 1.28% of the free float — a modest rebuild, but from a very low base. The absolute level remains near the lowest of the year, and the direction of travel echoes the pre-earnings positioning noted in prior notes: bears added ahead of the print, then pulled back. Borrow conditions offer no friction whatsoever. Availability is essentially uncapped, with over 1.1 billion shares available to lend and cost-to-borrow running at just 0.31%, down 38% over the past month. The ORTEX short score has nudged up to 31.9 from 30.5 two weeks ago — a mild increase but still a low absolute reading, sitting in the 72nd percentile for short score rank, which reflects limited bearish pressure rather than active conviction against the stock. Options traders have shifted slightly more defensive post-earnings: the put/call ratio edged up to 0.84, modestly above its 20-day mean of 0.80, though the z-score of 0.66 keeps it well within normal range. This is a market leaning cautiously rather than aggressively hedging.
The bull case rests on diversification and pipeline execution — Skyrizi and Rinvoq continuing to absorb the Humira biosimilar headwind, with the Allergan aesthetics franchise providing a non-correlated revenue stream. The bear case is more about altitude than fundamentals: the stock has run more than 20% from the mid-June trough, the two Neutral-rated analysts both have targets below the current price, and immunology competition combined with pricing pressure on Imbruvica remain structural concerns. Among peers, VRTX and AMGN both held up better on the week, with AMGN gaining 2.4% while ABBV gave back 3.2%. INCY was roughly flat. The relative weakness in ABBV this week — despite a broadly positive earnings reaction — suggests the post-Q2 repricing is stock-specific rather than sector-driven.
The institutional ownership base offers little near-term edge. BlackRock holds 8.5% and added modestly as of June 30. Capital Research built a more notable position, adding 11.5 million shares. The recent insider activity consists entirely of routine director awards from May — no open-market purchases or sales to signal conviction either way.
The next catalyst to watch is whether the $250 level holds as the first line of support, and whether the gap between the consensus target of $269.50 and the stock's current price narrows through earnings-driven revision or further price weakness.
See the live data behind this article on ORTEX.
Open ABBV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
